VCM
MRUS

Voleon Capital Management’s Merus MRUS Stock Holding History

Voleon Capital Management’s Portfolio MRUS Stock Details MRUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-34,493
Closed -$3.25M – 955
2025
Q3 		$3.25M Buy
+34,493
New +$2.25M 0.08% 247

Other funds holding MRUS

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
NAM
NTV Asset Management Charleston, West Virginia $1.02B AUM 31.16% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return
EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.72% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Voleon Capital Management's MRUS Position: Q4 2025 in Review

Voleon Capital Management sold out of Merus (MRUS) in Q4 2025, closing a stake of 34,493 shares — an estimated $3.25M sold.

Voleon Capital Management first reported a position in MRUS in Q3 2025 and held it in 1 quarter. The position peaked at $3.25M in Q3 2025. 10 funds tracked by Wall St. Rank hold MRUS as of Q4 2025.

  • Voleon Capital Management reported no remaining Merus position as of Q4 2025 after selling out during the quarter.
  • Voleon Capital Management sold 34,493 Merus shares in Q4 2025, an estimated $3.25M.
  • Voleon Capital Management first reported a position in Merus in Q3 2025 and held it in 1 quarter.
  • Voleon Capital Management's Merus position peaked at $3.25M in Q3 2025.
  • 10 funds tracked by Wall St. Rank held Merus as of Q4 2025.

Based on Voleon Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.